Dovato as effective as Biktarvy for maintenance therapy of HIV-1

23 July 2024

HIV specialist ViiV Healthcare, which is majority owned by UK pharma major GSK (LSE: GSK), today announced 48-week findings from PASO DOBLE (GeSIDA 11720 study).

ViiV noted that this is the largest head-to-head, Phase IV randomized clinical trial (RCT) investigating the two- drug regimen Dovato (dolutegravir/lamivudine [DTG/[3TC]) compared to the three-drug regimen with Gilead Sciences’ (Nasdaq: GILD) blockbuster drug Biktarvy (bictegravir/emtricitabine]/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for the treatment of HIV-1 in people who are virologically suppressed and who could benefit from treatment optimization.

Findings showed that switching to DTG/3TC in virologically suppressed adults living with HIV demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to BIC/FTC/TAF. These data will be presented at the 25th International AIDS Conference (AIDS 2024), held in Munich, Germany (July (22-26).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK